nicotine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1920	54-11-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nicotine L-Nicotine (S)-Nicotine (-)-Nicotine nicotine bitartrate anhydrous nicotine polacrilex	Devices or delivery systems used to aid in ending a TOBACCO habit. Molecular weight: 162.24 Formula: C10H14N2 CLOGP: 0.88 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 16.13 ALOGS: -0.24 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nicotine
L-Nicotine
(S)-Nicotine
(-)-Nicotine
nicotine bitartrate anhydrous
nicotine polacrilex

Devices or delivery systems used to aid in ending a TOBACCO habit.

Molecular weight: 162.24
Formula: C10H14N2
CLOGP: 0.88
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 16.13
ALOGS: -0.24
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	Chewing gum
60	mg	Inhal
30	mg	N
30	mg	SL
14	mg	TD

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	16.70 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.52 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	18 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.95 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 7, 1991	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nicotine dependence	541.27	13.13	101	14640	535	53333790
Drug withdrawal syndrome neonatal	278.99	13.13	73	14668	2077	53332248
Drug dependence	256.29	13.13	123	14618	21349	53312976
Macular degeneration	241.42	13.13	100	14641	12261	53322064
Foetal exposure during pregnancy	208.55	13.13	126	14615	34589	53299736
Incorrect product administration duration	207.63	13.13	86	14655	10538	53323787
Premature delivery	205.52	13.13	113	14628	25991	53308334
Product adhesion issue	173.33	13.13	63	14678	5434	53328891
Overdose	170.84	13.13	178	14563	107558	53226767
Maternal exposure during pregnancy	145.10	13.13	196	14545	155443	53178882
Myocardial stunning	100.56	13.13	20	14721	155	53334170
Intentional product misuse	84.29	13.13	85	14656	49307	53285018
Application site erythema	82.17	13.13	36	14705	5055	53329270
Jaundice neonatal	80.30	13.13	23	14718	921	53333404
Accidental overdose	80.24	13.13	58	14683	21421	53312904
Dependence	76.78	13.13	27	14714	2114	53332211
Application site pruritus	72.39	13.13	31	14710	4118	53330207
Necrosis ischaemic	68.93	13.13	20	14721	839	53333486
Rhesus incompatibility	67.29	13.13	13	14728	85	53334240
Drug abuse	66.26	13.13	86	14655	65440	53268885
Exposure during pregnancy	65.59	13.13	121	14620	124739	53209586
Poor feeding infant	64.80	13.13	15	14726	252	53334073
Premature baby	63.96	13.13	49	14692	19752	53314573
Rheumatoid arthritis	62.49	13.13	7	14734	314524	53019801
Product quality issue	61.85	13.13	63	14678	36960	53297365
Pneumonia streptococcal	58.54	13.13	21	14720	1742	53332583
Oligohydramnios	55.33	13.13	29	14712	6047	53328278
Beta haemolytic streptococcal infection	52.08	13.13	20	14721	2007	53332318
Maternal exposure during breast feeding	51.40	13.13	23	14718	3394	53330931
Tobacco abuse	46.47	13.13	14	14727	670	53333655
Low birth weight baby	45.92	13.13	26	14715	6311	53328014
Rib deformity	43.03	13.13	10	14731	171	53334154
Chronic obstructive pulmonary disease	42.34	13.13	67	14674	61006	53273319
Exposure via breast milk	42.17	13.13	16	14725	1554	53332771
Treatment noncompliance	39.20	13.13	47	14694	32988	53301337
Application site rash	36.92	13.13	17	14724	2679	53331646
Congenital tricuspid valve incompetence	36.84	13.13	8	14733	99	53334226
Application site reaction	36.50	13.13	12	14729	765	53333560
Anxiety	34.47	13.13	126	14615	196578	53137747
Congenital pulmonary hypertension	33.33	13.13	7	14734	73	53334252
Substance abuse	31.38	13.13	18	14723	4476	53329849
Reversible cerebral vasoconstriction syndrome	30.26	13.13	14	14727	2231	53332094
Developmental hip dysplasia	30.20	13.13	12	14729	1318	53333007
Premature separation of placenta	29.47	13.13	13	14728	1854	53332471
Toxicity to various agents	29.13	13.13	129	14612	219469	53114856
Agitation neonatal	28.30	13.13	9	14732	516	53333809
Caesarean section	28.05	13.13	29	14712	17291	53317034
Maternal drugs affecting foetus	27.89	13.13	18	14723	5528	53328797
Dysmetropsia	27.57	13.13	6	14735	75	53334250
Loss of proprioception	26.90	13.13	8	14733	366	53333959
Fatigue	26.61	13.13	108	14633	730398	52603927
Alopecia	26.52	13.13	16	14725	234567	53099758
Application site irritation	26.30	13.13	12	14729	1852	53332473
Axonal neuropathy	25.95	13.13	10	14731	1013	53333312
Nasal obstruction	25.40	13.13	10	14731	1072	53333253
Xanthogranuloma	25.11	13.13	4	14737	6	53334319
Reversible airways obstruction	24.86	13.13	10	14731	1134	53333191
Throat clearing	24.85	13.13	10	14731	1135	53333190
Arthropathy	23.84	13.13	5	14736	141448	53192877
Application site swelling	23.53	13.13	8	14733	566	53333759
Abnormal dreams	23.31	13.13	21	14720	10580	53323745
Off label use	23.26	13.13	61	14680	472151	52862174
Symphysiolysis	23.24	13.13	4	14737	12	53334313
Premature labour	22.41	13.13	22	14719	12340	53321985
Drug intolerance	21.87	13.13	15	14726	205478	53128847
Application site dermatitis	21.59	13.13	6	14735	215	53334110
Abortion induced	21.00	13.13	20	14721	10806	53323519
Joint swelling	20.23	13.13	21	14720	234617	53099708
Pain	20.14	13.13	89	14652	588309	52746016
Irritability	20.13	13.13	33	14708	30920	53303405
Respiratory failure	19.83	13.13	67	14674	100445	53233880
Cardiac death	19.80	13.13	7	14734	556	53333769
Application site vesicles	19.15	13.13	9	14732	1485	53332840
Treatment failure	18.85	13.13	6	14735	128397	53205928
Pre-eclampsia	18.75	13.13	17	14724	8630	53325695
Therapeutic product effect decreased	18.22	13.13	6	14735	125649	53208676
Systemic lupus erythematosus	18.16	13.13	6	14735	125408	53208917
Oophoritis	18.10	13.13	4	14737	54	53334271
Drug screen positive	18.08	13.13	12	14729	3860	53330465
Arthralgia	17.92	13.13	62	14679	439721	52894604
Nightmare	17.46	13.13	23	14718	17728	53316597
Withdrawal syndrome	17.44	13.13	24	14717	19277	53315048
Application site pain	17.24	13.13	12	14729	4171	53330154
Prinzmetal angina	17.22	13.13	7	14734	816	53333509
Selective eating disorder	16.85	13.13	9	14732	1949	53332376
Megacolon	16.81	13.13	9	14732	1957	53332368
Foetal distress syndrome	16.76	13.13	8	14733	1367	53332958
Application site burn	16.69	13.13	7	14734	883	53333442
Loss of consciousness	16.58	13.13	69	14672	114143	53220182
Application site scar	16.40	13.13	5	14736	249	53334076
Tobacco poisoning	16.13	13.13	4	14737	91	53334234
Sneezing	15.98	13.13	20	14721	14652	53319673
Schizoaffective disorder	15.95	13.13	9	14732	2168	53332157
Full blood count abnormal	15.75	13.13	11	14730	3844	53330481
False positive investigation result	15.50	13.13	6	14735	615	53333710
Foetal growth restriction	15.36	13.13	14	14727	7160	53327165
Suicidal ideation	15.32	13.13	44	14697	60467	53273858
Drug abuser	15.28	13.13	10	14731	3143	53331182
Patent ductus arteriosus	15.10	13.13	11	14730	4107	53330218
Tobacco interaction	14.78	13.13	3	14738	26	53334299
Pyrexia	14.37	13.13	60	14681	403133	52931192
Contraindicated product administered	14.29	13.13	10	14731	135619	53198706
Nervousness	14.27	13.13	28	14713	30150	53304175
Infection	14.18	13.13	16	14725	172189	53162136
Gastric dilatation	13.69	13.13	6	14735	842	53333483
Plethysmography	13.68	13.13	3	14738	39	53334286
Application site warmth	13.67	13.13	4	14737	173	53334152
Drug withdrawal syndrome	13.25	13.13	26	14715	27996	53306329
Hallucination, synaesthetic	13.22	13.13	3	14738	46	53334279

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nicotine dependence	380.93	13.47	77	12154	461	32500834
Drug withdrawal syndrome neonatal	286.05	13.47	89	12142	3475	32497820
Drug dependence	270.32	13.47	145	12086	23339	32477956
Incorrect product administration duration	228.67	13.47	79	12152	4299	32496996
Foetal exposure during pregnancy	213.26	13.47	153	12078	41148	32460147
Intentional product misuse	166.70	13.47	125	12106	35926	32465369
Accidental overdose	136.42	13.47	87	12144	19252	32482043
Overdose	130.40	13.47	162	12069	86915	32414380
Product adhesion issue	121.15	13.47	38	12193	1521	32499774
Maternal exposure during breast feeding	102.98	13.47	34	12197	1606	32499689
Premature baby	96.34	13.47	69	12162	18449	32482846
Low birth weight baby	74.29	13.47	41	12190	6953	32494342
Dependence	70.82	13.47	24	12207	1229	32500066
Jaundice neonatal	68.28	13.47	23	12208	1156	32500139
Alcohol abuse	66.94	13.47	33	12198	4439	32496856
Exposure via breast milk	62.30	13.47	24	12207	1778	32499517
Toxicity to various agents	61.51	13.47	176	12055	177865	32323430
Foetal disorder	60.79	13.47	19	12212	751	32500544
Tobacco poisoning	53.15	13.47	9	12222	15	32501280
Neutropenia neonatal	50.82	13.47	16	12215	648	32500647
Drug abuser	48.52	13.47	26	12205	4158	32497137
Drug screen positive	48.19	13.47	26	12205	4215	32497080
Alcohol interaction	46.95	13.47	21	12210	2268	32499027
Tremor neonatal	44.53	13.47	13	12218	406	32500889
Poor feeding infant	42.49	13.47	13	12218	478	32500817
Body temperature abnormal	37.05	13.47	12	12219	533	32500762
Foetal distress syndrome	35.86	13.47	14	12217	1075	32500220
Application site pruritus	35.85	13.47	15	12216	1378	32499917
Substance abuse	35.84	13.47	26	12205	7081	32494214
Breech presentation	35.33	13.47	9	12222	166	32501129
Drug abuse	34.35	13.47	86	12145	80157	32421138
Tobacco abuse	31.93	13.47	10	12221	398	32500897
Drug use disorder	29.84	13.47	18	12213	3603	32497692
Withdrawal syndrome	29.23	13.47	29	12202	12093	32489202
Off label use	29.08	13.47	44	12187	306276	32195019
Application site erythema	28.40	13.47	15	12216	2328	32498967
Schizophrenia	28.08	13.47	26	12205	9958	32491337
Laryngeal dysplasia	27.54	13.47	4	12227	0	32501295
Application site reaction	26.95	13.47	9	12222	440	32500855
Agitation neonatal	25.48	13.47	11	12220	1091	32500204
Tobacco user	25.09	13.47	9	12222	546	32500749
Drug withdrawal syndrome	24.53	13.47	34	12197	20197	32481098
Product quality issue	24.34	13.47	33	12198	19200	32482095
Tachycardia	23.26	13.47	74	12157	79014	32422281
Venolymphatic malformation	23.24	13.47	5	12226	42	32501253
Application site rash	21.42	13.47	9	12222	835	32500460
Treatment noncompliance	20.82	13.47	37	12194	27165	32474130
Acne infantile	20.18	13.47	5	12226	82	32501213
Diarrhoea	19.62	13.47	71	12160	364731	32136564
Renal hypoplasia	19.54	13.47	5	12226	94	32501201
Application site scar	19.11	13.47	4	12227	29	32501266
Renal impairment	18.12	13.47	6	12225	91966	32409329
Pulmonary valve stenosis congenital	17.48	13.47	5	12226	145	32501150
Application site vesicles	17.29	13.47	7	12224	591	32500704
Myoclonic epilepsy	17.01	13.47	8	12223	970	32500325
Weight decrease neonatal	16.85	13.47	6	12225	356	32500939
Breathing-related sleep disorder	16.39	13.47	5	12226	182	32501113
Anxiety	15.99	13.47	75	12156	95930	32405365
Palpitations	15.84	13.47	39	12192	35930	32465365
Application site urticaria	15.74	13.47	4	12227	73	32501222
Antipsychotic drug level increased	15.70	13.47	12	12219	3534	32497761
Euphoric mood	15.45	13.47	14	12217	5213	32496082
Application site discolouration	15.20	13.47	5	12226	233	32501062
Application site pain	15.09	13.47	9	12222	1765	32499530
Drug tolerance increased	15.07	13.47	6	12225	485	32500810
Insomnia	14.99	13.47	76	12155	100272	32401023
Necrotising ulcerative gingivostomatitis	14.95	13.47	4	12227	90	32501205
Death	14.83	13.47	84	12147	382433	32118862
Knee deformity	14.47	13.47	6	12225	539	32500756
Nightmare	14.30	13.47	21	12210	13145	32488150
Neonatal disorder	14.11	13.47	7	12224	954	32500341
Emphysema	14.10	13.47	18	12213	9879	32491416
Potentiating drug interaction	14	13.47	13	12218	4995	32496300
Left ventricular hypertrophy	13.95	13.47	15	12216	6865	32494430
Facial asymmetry	13.89	13.47	5	12226	306	32500989
Rhesus incompatibility	13.76	13.47	3	12228	27	32501268
Maternal drugs affecting foetus	13.73	13.47	12	12219	4265	32497030

Pharmacologic Action:

Source	Code	Description
ATC	N07BA01	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in nicotine dependence
FDA CS	M0014836	Nicotine
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018679	Cholinergic Agonists
MeSH PA	D005731	Ganglionic Stimulants
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018722	Nicotinic Agonists
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D000077444	Smoking Cessation Agents
FDA EPC	N0000175706	Cholinergic Nicotinic Agonist
CHEBI has role	CHEBI:22917	botanical insecticides
CHEBI has role	CHEBI:35471	psychopharmaceuticals
CHEBI has role	CHEBI:35474	minor tranquilisers
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:47958	muscarinic agonists
CHEBI has role	CHEBI:49110	peripheral nervous system agent
CHEBI has role	CHEBI:50846	Biomodulator
CHEBI has role	CHEBI:50905	teratogen
CHEBI has role	CHEBI:50910	agente neurotoxico
CHEBI has role	CHEBI:52290	mitogens
CHEBI has role	CHEBI:59163	biological marker
CHEBI has role	CHEBI:76924	plant metabolites

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Nicotine dependence	indication	56294008	DOID:0050742
Smoking cessation assistance	indication	384742004
Pellagra	indication	418186002	DOID:8457
Niacin deficiency	indication	418279001
Nicotine Withdrawal Symptoms	indication
Hyperlipidemia	off-label use	55822004	DOID:1168
Hypophosphatemia	contraindication	4996001
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Esophagitis	contraindication	16761005	DOID:11963
Myocardial infarction	contraindication	22298006	DOID:5844
Hyperthyroidism	contraindication	34486009	DOID:7998
Temporomandibular joint disorder	contraindication	41888000
Low blood pressure	contraindication	45007003
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Thromboangiitis obliterans	contraindication	52403007	DOID:12918
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Prinzmetal angina	contraindication	87343002
Gout	contraindication	90560007	DOID:13189
Magnetic resonance imaging	contraindication	113091000
Liver function tests abnormal	contraindication	166603001
Angina pectoris	contraindication	194828000
Arterial hemorrhage	contraindication	234003006
Disease of liver	contraindication	235856003	DOID:409
Raynaud's phenomenon	contraindication	266261006
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Pheochromocytoma	contraindication	302835009
Acute coronary syndrome	contraindication	394659003
Pharyngitis	contraindication	405737000	DOID:2275
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000
Life-Threatening Cardiac Arrhythmias	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.05	Basic
pKa2	3.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Neuronal acetylcholine receptor; alpha4/beta2	Ion channel	P17787 P43681	ACHB2_HUMAN ACHA4_HUMAN	AGONIST	Ki	8.56	WOMBAT-PK	CHEMBL
Potassium voltage-gated channel subfamily D member 3	Ion channel	Q9UK17	KCND3_HUMAN		IC50	7.40	WOMBAT-PK
Cytochrome P450 2A6	Enzyme	P11509	CP2A6_HUMAN		IC50	5.36	WOMBAT-PK
Transient receptor potential cation channel subfamily A member 1	Ion channel	O75762	TRPA1_HUMAN	ACTIVATOR	EC50	4.80	IUPHAR
Neuronal acetylcholine receptor; alpha2/beta4	Ion channel	P30926 Q15822	ACHB4_HUMAN ACHA2_HUMAN		Ki	7.15	CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2	Ion channel	P17787 Q15822	ACHB2_HUMAN ACHA2_HUMAN		Ki	8.26	CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4	Ion channel	P30926 P32297	ACHB4_HUMAN ACHA3_HUMAN		Ki	5.95	WOMBAT-PK
Neuronal acetylcholine receptor; alpha3/beta2	Ion channel	P17787 P32297	ACHB2_HUMAN ACHA3_HUMAN		Ki	7.85	WOMBAT-PK
Neuronal acetylcholine receptor; alpha4/beta4	Ion channel	P30926 P43681	ACHB4_HUMAN ACHA4_HUMAN		Ki	7.64	CHEMBL
Serotonin 3 (5-HT3) receptor	Ion channel	A5X5Y0 O95264 P46098 Q70Z44 Q8WXA8	5HT3E_HUMAN 5HT3B_HUMAN 5HT3A_HUMAN 5HT3D_HUMAN 5HT3C_HUMAN		Ki	4.15	CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma	Ion channel	P02708 P07510 P11230 Q07001	ACHA_HUMAN ACHG_HUMAN ACHB_HUMAN ACHD_HUMAN		Ki	5.83	CHEMBL
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3	Ion channel	P17787 P32297 Q05901 Q15825	ACHB2_HUMAN ACHA3_HUMAN ACHB3_HUMAN ACHA6_HUMAN		IC50	7.07	CHEMBL
Acetylcholine receptor subunit alpha	Ion channel	P02708	ACHA_HUMAN		IC50	4.68	CHEMBL
Neuronal acetylcholine receptor subunit alpha-3	Ion channel	P32297	ACHA3_HUMAN		IC50	7.35	CHEMBL
Neuronal acetylcholine receptor subunit alpha-7	Ion channel	P36544	ACHA7_HUMAN		Ki	5.39	WOMBAT-PK
Acetylcholine-binding protein	Unclassified		ACHP_LYMST		Ki	7.20	CHEMBL
Acetylcholine receptor subunit delta	Ion channel		ACHD_TORCA		Ki	9	CHEMBL
Neuronal acetylcholine receptor subunit alpha-4	Ion channel		ACHA4_RAT		Ki	9.03	CHEMBL
Neuronal acetylcholine receptor subunit alpha-7	Ion channel		ACHA7_RAT		Ki	6.89	CHEMBL
Neuronal acetylcholine receptor subunit alpha-7	Ion channel		ACHA7_MOUSE		Ki	6.61	CHEMBL
Neuronal acetylcholine receptor subunit alpha-9	Ion channel		ACHA9_RAT		Kd	8.30	CHEMBL
Neuronal acetylcholine receptor subunit beta-4	Ion channel		ACHB4_RAT		Ki	7.14	CHEMBL
Neuronal acetylcholine receptor subunit alpha-3	Ion channel		ACHA3_RAT		Ki	7.33	CHEMBL
Neuronal acetylcholine receptor subunit alpha-2	Ion channel		ACHA2_RAT		Ki	7.92	CHEMBL
Soluble acetylcholine receptor	Unclassified		Q8WSF8_APLCA		Ki	7.52	CHEMBL
Acetylcholine receptor subunit alpha	Ion channel		ACHA_TORCA		IC50	4.64	CHEMBL
Lycopene cyclase	Enzyme		CRTY_PANAN		IC50	5.32	CHEMBL
Nicotinic acetylcholine receptor alpha 5 subunit	Ion channel		A9XFY4_MUSDO		Ki	5.61	CHEMBL
Acetylcholine receptor subunit beta-like 2	Ion channel		ACH4_DROME		Ki	5.57	CHEMBL
Neuronal acetylcholine receptor subunit alpha-4	Ion channel		ACHA4_CHICK		Ki	8.72	CHEMBL
Neuronal acetylcholine receptor subunit alpha-4	Ion channel		ACHA4_MOUSE		IC50	8.15	CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2	Ion channel		ACHA2_RAT ACHB2_RAT		Ki	8.26	CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2	Ion channel		ACHA3_RAT ACHB2_RAT		Ki	9	CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4	Ion channel		ACHA3_RAT ACHB4_RAT		Ki	6.70	CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2	Ion channel		ACHA4_RAT ACHB2_RAT		Kd	9.40	CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4	Ion channel		ACHA4_RAT ACHB4_RAT		Ki	8.26	CHEMBL
Neuronal acetylcholine receptor	Ion channel		ACHA3_RAT ACHA4_RAT ACHA2_RAT ACHB2_RAT ACHB3_RAT ACHB4_RAT ACHA5_RAT ACHA_RAT ACHB_RAT ACHA6_RAT ACHA9_RAT ACHA7_RAT ACH10_RAT		Kd	11	CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4	Ion channel		ACHA2_RAT ACHB4_RAT		Ki	7.15	CHEMBL
Acetylcholine receptor	Ion channel		ACHA_TORCA ACHB_TORCA ACHG_TORCA ACHD_TORCA		Ki	5.20	CHEMBL
Muscarinic acetylcholine receptor	GPCR		ACM1_RAT ACM3_RAT ACM4_RAT ACM5_RAT ACM2_RAT		IC50	4.55	CHEMBL
Transient receptor potential cation channel subfamily A member 1	Ion channel		TRPA1_MOUSE		EC50	5	CHEMBL
Potassium voltage-gated channel subfamily D member 3	Ion channel		KCND3_RAT	BLOCKER	IC50	7.40	IUPHAR

External reference:

ID	Source
4020286	VUID
N0000148163	NUI
D03365	KEGG_DRUG
65-31-6	SECONDARY_CAS_RN
4018610	VANDF
4020286	VANDF
C0028040	UMLSCUI
CHEBI:17688	CHEBI
NCT	PDB_CHEM_ID
CHEMBL3	ChEMBL_ID
DB00184	DRUGBANK_ID
D009538	MESH_DESCRIPTOR_UI
89594	PUBCHEM_CID
2585	IUPHAR_LIGAND_ID
6M3C89ZY6R	UNII
1306106	RXNORM
11529	MMSL
5173	MMSL
5174	MMSL
72003	MMSL
d00316	MMSL
001770	NDDF
003575	NDDF
323283001	SNOMEDCT_US
68540007	SNOMEDCT_US
77544001	SNOMEDCT_US
D061485	MESH_DESCRIPTOR_UI
CHEMBL1201536	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nicotrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5400	INHALANT	4 mg	RESPIRATORY (INHALATION)	NDA	29 sections
Nicotrol	HUMAN PRESCRIPTION DRUG LABEL	1	0009-5401	SPRAY, METERED	10 mg	NASAL	NDA	28 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0029	GUM, CHEWING	2 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0053	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0170	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
good sense nicotinemint	HUMAN OTC DRUG LABEL	1	0113-0206	GUM, CHEWING	2 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0344	LOZENGE	2 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0422	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0456	GUM, CHEWING	2 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0532	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-0704	GUM, CHEWING	2 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-0713	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0734	LOZENGE	2 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-0749	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-0761	GUM, CHEWING	2 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0854	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
good sense nicotine	HUMAN OTC DRUG LABEL	1	0113-0873	LOZENGE	4 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-0957	LOZENGE	4 mg	ORAL	ANDA	15 sections
Good Sense Nicotine	HUMAN OTC DRUG LABEL	1	0113-1125	LOZENGE	2 mg	ORAL	ANDA	15 sections
good sense nicotine	HUMAN OTC DRUG LABEL	1	0113-1190	LOZENGE	4 mg	ORAL	ANDA	15 sections
good sense nicotine	HUMAN OTC DRUG LABEL	1	0113-1352	GUM, CHEWING	2 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-7007	LOZENGE	4 mg	ORAL	ANDA	14 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-7008	LOZENGE	2 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-7029	GUM, CHEWING	2 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-7124	LOZENGE	2 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-7170	GUM, CHEWING	4 mg	ORAL	ANDA	15 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-7190	LOZENGE	4 mg	ORAL	ANDA	15 sections
Basic Care nicotine	HUMAN OTC DRUG LABEL	1	0113-7201	LOZENGE	2 mg	ORAL	ANDA	14 sections
Basic Care nicotine	HUMAN OTC DRUG LABEL	1	0113-7203	LOZENGE	4 mg	ORAL	ANDA	14 sections
basic care nicotine	HUMAN OTC DRUG LABEL	1	0113-7344	LOZENGE	2 mg	ORAL	ANDA	15 sections